Related references
Note: Only part of the references are listed.Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists
Edwin Bremer et al.
CANCER RESEARCH (2008)
Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4
M. Todaro et al.
CELL DEATH AND DIFFERENTIATION (2008)
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody
Anil Shanker et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein
Julia Stieglmaier et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver
Xandra Volkmann et al.
HEPATOLOGY (2007)
TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2
Alessandro Natoni et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis
Ronald Koschny et al.
CLINICAL CANCER RESEARCH (2007)
Activation of CD95L fusion protein prodrugs by tumor-associated proteases
I. Watermann et al.
CELL DEATH AND DIFFERENTIATION (2007)
Clinical implications of fibroblast activation protein in patients with colon cancer
Leonard R. Henry et al.
CLINICAL CANCER RESEARCH (2007)
TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window
Ronald Koschny et al.
HEPATOLOGY (2007)
Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak
Simon N. Willis et al.
SCIENCE (2007)
Biology of RANK, RANKL, and osteoprotegerin
Brendan F. Boyce et al.
ARTHRITIS RESEARCH & THERAPY (2007)
The promise of TRAIL - potential and risks of a novel anticancer therapy
Ronald Koschny et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2007)
TRAIL signalling: Decisions between life and death
Christina Falschlehner et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report
J. S. Norris et al.
CANCER GENE THERAPY (2006)
Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface
Jeannette Gerspach et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma
A. Trauzold et al.
ONCOGENE (2006)
TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy
Esther H. J. Wissink et al.
RADIOTHERAPY AND ONCOLOGY (2006)
Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human
Claudia Bossen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts
Yuying Liu et al.
NEOPLASIA (2006)
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs
TM Ganten et al.
CLINICAL CANCER RESEARCH (2006)
The role of receptor internalization in CD95 signaling
KH Lee et al.
EMBO JOURNAL (2006)
HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL
A Pathil et al.
HEPATOLOGY (2006)
Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug
J Gerspach et al.
CELL DEATH AND DIFFERENTIATION (2006)
TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer
E Cretney et al.
IMMUNOLOGY AND CELL BIOLOGY (2006)
Eradication of established tumors in mice by a combination antibody-based therapy
Tomoyasu Uno et al.
NATURE MEDICINE (2006)
Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha
A Sacchi et al.
CLINICAL CANCER RESEARCH (2006)
DNA damage-induced cell death by apoptosis
Wynand P. Roos et al.
TRENDS IN MOLECULAR MEDICINE (2006)
A humanized anti-human Fas antibody, R-125224, induces apoptosis in type I activated lymphocytes but not in type II cells
J Nakayama et al.
INTERNATIONAL IMMUNOLOGY (2006)
Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells
N Ishimura et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2006)
mTOR controls FLIPs translation and TRAIL sensitivity in glioblastoma multiforme cells
A Panner et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL
TM Ganten et al.
HEPATOLOGY (2005)
Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer
MM McCarthy et al.
CLINICAL CANCER RESEARCH (2005)
Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1
M MacFarlane et al.
CELL DEATH AND DIFFERENTIATION (2005)
The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice
BL Hylander et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2005)
c-FLIPR, a new regulator of death receptor-induced apoptosis
A Golks et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR
E Bremer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Tumor therapeutics by design: targeting and activation of death receptors
H Wajant et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer
S Sudarshan et al.
CANCER GENE THERAPY (2005)
Elimination of rheumatoid synovium in situ using a Fas ligand 'gene scalpel'
HD Zhang et al.
ARTHRITIS RESEARCH & THERAPY (2005)
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
A Nebbioso et al.
NATURE MEDICINE (2005)
Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2
E Bremer et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Optimal site-specific PEGylation of mutant TNF-α improves its antitumor potency
Y Yoshioka et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy
K Takeda et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Cell death: Critical control points
NN Danial et al.
CELL (2004)
Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells
E Bremer et al.
NEOPLASIA (2004)
Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells
S Nakata et al.
ONCOGENE (2004)
Targeting death receptors in cancer with Apo2/TRAIL
SK Kelley et al.
CURRENT OPINION IN PHARMACOLOGY (2004)
Functionalization of tumor necrosis factor-α using phage display technique and PEGylation improves its antitumor therapeutic window
H Shibata et al.
CLINICAL CANCER RESEARCH (2004)
Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies
S Inoue et al.
CELL DEATH AND DIFFERENTIATION (2004)
Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells
F Van Valen et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes
M Ogris et al.
JOURNAL OF CONTROLLED RELEASE (2003)
Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted activation
D Samel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes
O Micheau et al.
CELL (2003)
Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity
Y Yamamoto et al.
NATURE BIOTECHNOLOGY (2003)
Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT
VJ Wroblewski et al.
BIOCHEMICAL PHARMACOLOGY (2003)
Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation
M Leverkus et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand
PG Knox et al.
JOURNAL OF IMMUNOLOGY (2003)
Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector
S Rubinchik et al.
CANCER GENE THERAPY (2003)
Tumor necrosis factor signaling
H Wajant et al.
CELL DEATH AND DIFFERENTIATION (2003)
Generation of human interferon gamma and tumor necrosis factor alpha chimeric TNT-3 fusion proteins
J Sharifi et al.
HYBRIDOMA AND HYBRIDOMICS (2002)
The long form of FLIP is an activator of caspase-8 at the fas death-inducing signaling complex
O Micheau et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Radiation-induced tumour necrosis factor-α expression:: clinical application of transcriptional and physical targeting of gene therapy
RR Weichselbaum et al.
LANCET ONCOLOGY (2002)
TNFerade Biologic: Preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene
H Rasmussen et al.
CANCER GENE THERAPY (2002)
Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia
M MacFarlane et al.
ONCOGENE (2002)
TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy
H Wajant et al.
APOPTOSIS (2002)
Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis
GJ Atkins et al.
BONE (2002)
Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8
MR Sprick et al.
EMBO JOURNAL (2002)
TNF-Selectokine:: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor
T Wüest et al.
ONCOGENE (2002)
Biologic sequelae of nuclear factor-κB blockade in multiple myeloma:: therapeutic applications
N Mitsiades et al.
BLOOD (2002)
Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment
R Kircheis et al.
GENE THERAPY (2002)
Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma
VK Gupta et al.
ANNALS OF SURGICAL ONCOLOGY (2002)
Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRIAL-induced apoptosis
A Evdokiou et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
T Poynard et al.
GASTROENTEROLOGY (2002)
Three-dimensional structure of the apoptosome: Implications for assembly, procaspase-9 binding, and activation
D Acehan et al.
MOLECULAR CELL (2002)
Immunobiology of tumor necrosis factor receptor superfamily
T Zhou et al.
IMMUNOLOGIC RESEARCH (2002)
Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8.
FC Kischkel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D
A Olsson et al.
LEUKEMIA (2001)
A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression
S Rubinchik et al.
MOLECULAR THERAPY (2001)
Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus
TS Griffith et al.
MOLECULAR THERAPY (2001)
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
CS Mitsiades et al.
BLOOD (2001)
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
K Ichikawa et al.
NATURE MEDICINE (2001)
Potential and caveats of TRAIL in cancer therapy
J Held et al.
DRUG RESISTANCE UPDATES (2001)
The kiss of death: promises and failures of death receptors and ligands in cancer therapy
PT Daniel et al.
LEUKEMIA (2001)
Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1
R Di Pietro et al.
BLOOD (2001)
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
D Lawrence et al.
NATURE MEDICINE (2001)
Extracellular matrix interacts with soluble CD95L: Retention and enhancement of cytotoxicity
K Aoki et al.
NATURE IMMUNOLOGY (2001)
Executioner caspase-3,-6, and-7 perform distinct, non-redundant roles during the demolition phase of apoptosis
EA Slee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis
SM Srinivasula et al.
NATURE (2001)
Tumor necrosis factor receptor-associated factor (TRAF) 2 and its role in TNF signaling
H Wajant et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2001)
Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
F Curnis et al.
NATURE BIOTECHNOLOGY (2000)
Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells
K Clodi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis
ML Hyer et al.
MOLECULAR THERAPY (2000)
Temperature-sensitive differential affinity of TRAIL for its receptors - DR5 is the highest affinity receptor
A Truneh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins
AM Verhagen et al.
CELL (2000)
A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling
FKM Chan et al.
SCIENCE (2000)
Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy
K Aoki et al.
MOLECULAR THERAPY (2000)
A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity
K Ichikawa et al.
INTERNATIONAL IMMUNOLOGY (2000)
The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation
A Devin et al.
IMMUNITY (2000)
Share Paper
